- Home
- CNOBP vs BRTX Comparison
CNOBP vs BRTX Comparison
Compare CNOBP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOBP | BRTX |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 493 | N/A |
| Industry | Major Banks | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 9.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CNOBP | BRTX |
|---|---|---|
| Price | $24.20 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 53.0K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | N/A | $0.98 |
| 52 Week High | N/A | $2.55 |
Technical Indicators
Market Signals| Indicator | CNOBP | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 52.59 |
| Support Level | $24.05 | $1.04 |
| Resistance Level | $24.24 | $1.16 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 87.11 | 88.16 |
Price Performance
Historical ComparisonAbout CNOBP ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.